David Bernard
Nephrology · New York, NYNPI 1518117712
Payments from drug & device makers
What this record shows
That places this record below the midpoint for nephrology clinicians in NY, where the typical reported total is $564.
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$6,230,752in research payments, 2019–2025
Across 431 payments — averaging $14,457 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bavarian Nordic A/s$2M
- Genentech, Inc.$1.3M
- AstraZeneca$694K
- Pfizer$427K
- Merck$416K
- Applied Therapeutics, Inc.$333K
- plus $1.1M from 19 others
How this compares
$0 in reported general payments places this provider in the 5th percentile of 935 nephrology providers in New York.
Other nephrology in New York
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
- Jai RadhakrishnanNew York$369K
- Girish NadkarniNew York$281K
- James ChevalierNew York$202K
- David CharytanNew York$164K
- Kirk CampbellNew York$152K
- Andrew BombackNew York$106K
- Alan PerlmanNew York$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.